Johnson Johnson Ownership

JNJ Stock  USD 155.17  0.33  0.21%   
Johnson Johnson has a total of 2.41 Billion outstanding shares. The majority of Johnson Johnson outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Johnson Johnson to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Johnson Johnson. Please pay attention to any change in the institutional holdings of Johnson Johnson as this could imply that something significant has changed or is about to change at the company. Please note that on November 15, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Johnson Johnson's common stock.
 
Shares in Circulation  
First Issued
2009-03-31
Previous Quarter
2.4 B
Current Value
2.4 B
Avarage Shares Outstanding
2.7 B
Quarterly Volatility
105.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Johnson Johnson in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Johnson Johnson, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
At this time, Johnson Johnson's Dividends Paid is relatively stable compared to the past year. Dividend Payout Ratio is expected to hike to 0.50 this year, although the value of Dividend Yield will most likely fall to 0.02. The value of Common Stock Shares Outstanding is expected to pull down to about 2.2 B. The value of Net Income Applicable To Common Shares is expected to pull down to about 13 B.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.

Johnson Stock Ownership Analysis

About 73.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.92. Johnson Johnson recorded earning per share (EPS) of 6.05. The entity last dividend was issued on the 26th of November 2024. The firm had 2:1 split on the 13th of June 2001. Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 141700 people. To learn more about Johnson Johnson call Alex Gorsky at 732 524 0400 or check out https://www.jnj.com.
Besides selling stocks to institutional investors, Johnson Johnson also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Johnson Johnson's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Johnson Johnson's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Johnson Johnson Quarterly Liabilities And Stockholders Equity

178.29 Billion

Johnson Johnson Insider Trades History

Less than 1% of Johnson Johnson are currently held by insiders. Unlike Johnson Johnson's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Johnson Johnson's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Johnson Johnson's insider trades
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Johnson Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Johnson Johnson is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Johnson Johnson backward and forwards among themselves. Johnson Johnson's institutional investor refers to the entity that pools money to purchase Johnson Johnson's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Bank Of America Corp2024-06-30
24.5 M
Legal & General Group Plc2024-06-30
23.3 M
Bank Of New York Mellon Corp2024-06-30
21.7 M
Massachusetts Financial Services Company2024-09-30
18.6 M
Fmr Inc2024-09-30
18.3 M
Wells Fargo & Co2024-06-30
18.1 M
Charles Schwab Investment Management Inc2024-09-30
17.6 M
Franklin Resources Inc2024-09-30
16.8 M
Amvescap Plc.2024-06-30
16.7 M
Vanguard Group Inc2024-09-30
231 M
Blackrock Inc2024-06-30
198.2 M
Note, although Johnson Johnson's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Johnson Johnson Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Johnson Johnson insiders, such as employees or executives, is commonly permitted as long as it does not rely on Johnson Johnson's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Johnson Johnson insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Johnson Johnson's latest congressional trading

Congressional trading in companies like Johnson Johnson, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Johnson Johnson by those in governmental positions are based on the same information available to the general public.
2024-11-15Senator Tommy TubervilleAcquired $15K to $50KVerify
2024-11-14Senator Tommy TubervilleAcquired $15K to $50KVerify
2024-10-11Representative Lloyd DoggettAcquired Under $15KVerify
2024-10-10Representative Lloyd DoggettAcquired Under $15KVerify
2024-09-06Representative John JamesAcquired Under $15KVerify
2024-09-02Representative John JamesAcquired Under $15KVerify
2024-08-20Senator Sheldon WhitehouseAcquired $15K to $50KVerify
2024-08-16Representative Kathy ManningAcquired Under $15KVerify
2024-08-08Representative Richard W AllenAcquired $15K to $50KVerify
2024-08-06Representative Jared MoskowitzAcquired Under $15KVerify
2024-07-15Representative Kevin HernAcquired Under $15KVerify
2024-07-10Representative Richard W AllenAcquired $15K to $50KVerify
2024-07-09Representative Josh GottheimerAcquired Under $15KVerify
2024-07-03Representative Lloyd DoggettAcquired Under $15KVerify
2024-04-12Representative Kevin HernAcquired Under $15KVerify
2024-01-24Representative Blake MooreAcquired Under $15KVerify
2024-01-17Senator Jerry MoranAcquired Under $15KVerify
2024-01-16Senator Jerry MoranAcquired Under $15KVerify
2024-01-13Representative Kevin HernAcquired Under $15KVerify
2023-11-16Senator Tommy TubervilleAcquired Under $15KVerify
2023-11-15Senator Tommy TubervilleAcquired Under $15KVerify
2023-10-20Senator Pete RickettsAcquired $100K to $250KVerify
2023-10-13Representative Kevin HernAcquired Under $15KVerify
2023-10-04Representative John CurtisAcquired Under $15KVerify
2023-10-03Senator Sheldon WhitehouseAcquired Under $15KVerify
2023-10-02Senator Sheldon WhitehouseAcquired Under $15KVerify
2023-08-10Representative Richard W AllenAcquired $15K to $50KVerify
2023-07-12Representative Kevin HernAcquired Under $15KVerify
2023-04-10Representative Kevin HernAcquired Under $15KVerify
2023-03-13Representative Lois FrankelAcquired Under $15KVerify
2023-03-11Representative Thomas H KeanAcquired $15K to $50KVerify
2023-02-11Representative Thomas H KeanAcquired $15K to $50KVerify
2023-01-13Representative Kevin HernAcquired Under $15KVerify
2022-12-08Representative Kurt SchraderAcquired Under $15KVerify
2022-11-18Representative Lois FrankelAcquired Under $15KVerify
2022-11-13Senator Shelley Moore CapitoAcquired Under $15KVerify
2022-11-12Senator Shelley Moore CapitoAcquired Under $15KVerify
2022-07-15Representative Kevin HernAcquired Under $15KVerify
2022-07-08Representative John CurtisAcquired Under $15KVerify
2022-06-09Representative Lois FrankelAcquired Under $15KVerify
2022-06-03Representative Cynthia AxneAcquired Under $15KVerify
2022-04-12Representative Kevin HernAcquired Under $15KVerify
2022-03-23Representative John CurtisAcquired Under $15KVerify
2022-02-03Senator Thomas R CarperAcquired Under $15KVerify
2022-02-02Senator Thomas R CarperAcquired Under $15KVerify
2022-01-11Representative Kevin HernAcquired Under $15KVerify
2021-10-18Representative Robert J WittmanAcquired Under $15KVerify
2021-10-07Representative Kevin HernAcquired $50K to $100KVerify
2021-07-17Representative Blake MooreAcquired Under $15KVerify
2021-07-15Representative Alan S LowenthalAcquired Under $15KVerify
2021-07-14Representative Kevin HernAcquired $250K to $500KVerify
2021-06-12Representative Richard W AllenAcquired $15K to $50KVerify
2021-05-06Representative Kathy ManningAcquired Under $15KVerify
2021-02-12Representative Austin ScottAcquired $15K to $50KVerify
2021-02-04Representative Kathy ManningAcquired Under $15KVerify
2020-11-14Representative Kevin HernAcquired Under $15KVerify
2020-09-08Representative K Michael ConawayAcquired $15K to $50KVerify
2020-08-25Representative Bob GibbsAcquired Under $15KVerify
2020-08-10Representative Josh GottheimerAcquired Under $15KVerify
2020-07-31Representative Bill PascrellAcquired $15K to $50KVerify
2020-04-29Senator Shelley Moore CapitoAcquired Under $15KVerify
2020-04-28Senator Shelley Moore CapitoAcquired Under $15KVerify
2020-01-14Representative Mike GallagherAcquired Under $15KVerify
2020-01-03Representative Mikie SherrillAcquired Under $15KVerify
2019-12-20Representative Lois FrankelAcquired Under $15KVerify
2019-02-14Representative John A YarmuthAcquired Under $15KVerify
2018-11-08Senator Shelley Moore CapitoAcquired Under $15KVerify
2018-11-07Senator Shelley Moore CapitoAcquired Under $15KVerify
2018-06-26Representative Earl BlumenauerAcquired Under $15KVerify
2018-06-22Representative Lois FrankelAcquired Under $15KVerify
2017-11-07Senator Tammy DuckworthAcquired Under $15KVerify
2017-07-03Senator James InhofeAcquired $50K to $100KVerify
2016-05-04Senator Shelley Moore CapitoAcquired Under $15KVerify
2016-05-03Senator Shelley Moore CapitoAcquired Under $15KVerify

Johnson Johnson Outstanding Bonds

Johnson Johnson issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Johnson Johnson uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Johnson bonds can be classified according to their maturity, which is the date when Johnson Johnson has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Johnson Johnson Corporate Filings

13th of November 2024
Other Reports
ViewVerify
6th of November 2024
Other Reports
ViewVerify
13A
1st of November 2024
An amended filing to the original Schedule 13G
ViewVerify
31st of October 2024
Other Reports
ViewVerify

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.89)
Dividend Share
4.86
Earnings Share
6.05
Revenue Per Share
36.428
Quarterly Revenue Growth
0.052
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.